Long-term gene expression in dividing and nondividing cells using SV40-derived vectors

Molecular Biotechnology

Volumn 34, Issue 2, 2006, Pages 257-270

  Strayer, David S ^a   Agrawal, Lokesh ^a   Cordelier, Pierre ^a   Liu, Bianling ^a   Louboutin, Jean Pierre ^a   Marusich, Elena ^a   McKee, Hayley J ^a   Ren, Carmen N NiGongyi ^a   Strayer, Marlene S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIUM; GENE DELIVERY SYSTEMS; NONDIVIDING CELLS; TRANSGENE EXPRESSION;

BIOMEDICAL ENGINEERING; BRAIN; GENE TRANSFER; PROTEINS; RNA;

CELLS;

CELL DNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MURINE LEUKEMIA VIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS ANTIGEN; SIMIAN VIRUS 40 VECTOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VIRUS VECTOR;

ANTIGENICITY; CELL DIVISION; CELL TYPE; CONFERENCE PAPER; DRUG SAFETY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MONKEY DISEASE; MUTAGENESIS; NONHUMAN; SIMIAN VIRUS 40; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL DIVISION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUTAGENESIS, INSERTIONAL; SIMIAN VIRUS 40; VIRUS INTEGRATION;

EID: 33845961331     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:34:2:257     Document Type: Conference Paper

References (108)

1. Monahan, P. E. and Samulski, R. J. (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Mol. Med. Today 6, 433-440.
2. Tal, J. (2000) Adeno-associated virus-based vectors in gene therapy. J. Biomed. Sci. 7, 279-291.
3. Amalfitano, A. and Parks, R. J. (2002) Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr. Gene Therapy 2, 111-133.
4. Young, L. S. and Mautner, V. (2001) The promise and potential hazards of adenovirus gene therapy. Gut 48, 733-736.
5. Weber, E., Anderson, W. F., and Kasahara, N. (2001) Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks. Curr. Opin. Molec. Ther. 3, 439-453.
6. Arad, U., Zeira, E., El-Latif, M. A., et al. (2005) Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method. Human Gene Therapy 16, 361-371.
7. Klimatcheva, E., Rosenblatt, J. D., and Planelles, V. (1999) Lentiviral vectors and gene therapy. Front. Biosci. 4, D481-D496.
8. Hammerschmidt, W. (2000) Herpesvirus vectors come of age. Curr. Opin. Molec. Ther. 2, 532-539.
9. Trobridge, G., Vassilopoulos, G., Josephson, N., and Russell, D. W. (2002) Gene transfer with foamy virus vectors. Meth. Enzymol. 346, 628-648.
10. Marusich, E. I., Parveen, Z., Strayer, D., Dornburg, R., and Pomerantz, R. J. (2005) Spleen necrosis virus (SNV)-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection. Virol. 332, 258-271.
11. Hallak, L. K., Merchan, J. R., Storgard, C. M., Loftus, J. C., and Russell, S. J. (2005) Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res. 65, 5292-5300.
12. Ebert, O., Harbaran, S., Shinozaki, K., and Woo, S. L. (2005) Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Therapy 12, 350-358.
13. Rheme, C., Ehrengruber, M. U., and Grandgirard, D. (2005) Alphaviral cytotoxicity and its implication in vector development. Exp. Physiol. 90, 45-52.
14. Quintana-Vazquez, D., Vazquez-Bloomquist, D. M., Galban Rodriguez, E., Herrera Buch, A. M., and Duarte Cano, C. A. (2005) A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia virus infection. Biotechnol. Appl. Biochem. 41, 59-66.
15. Nagorsen, D., Panelli, M., Dudley, M. E., Finkelstein, S. E., Rosenberg, S. A., and Marincola, F. M. (2003) Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther. 10, 1754-1765.
16. Wang, M., Tsou, T. H., Chen, L. S., et al. (2004) Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by JC virus-like particle. Hum. Gene Ther. 15, 1077-1090.
17. Sasaki, K., Inoue, M., Shibata, H., et al. (2005) Efficient and stable Sendai virus-mediated gene transfer into primate embryonic stem cells with pluripotency preserved. Gene Therapy 12, 203-210.
18. Hay, J. G. (2004) Sinbis virus: an effective targeted cancer therapeutic. Trends Biotechnol. 22, 501-503
19. Smyth, J. W., Fleeton, M. N., Sheahan, B. J., and Atkins, G. J. (2005) Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and derived vector. Gene Therapy 12, 147-159.
20. Ferrari S., Griesenbach, U., Shiraki-Iida, T., et al. (2004) A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Therapy 11, 1659-1664.
21. Gloriosco, J. C. and Fink, D. J. (2004) Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Ann. Rev. Microbiol. 58, 253-271.
22. Wang, L., Kaneko, S., Honda, M., and Kobayashi, K. (2002) Approach to establishing a liver targeting gene therapeutic vector using naturally occurring defective hepatitis B viruses devoid of immunogenic T cell epitope. Virus Res. 85, 187-197.
23. Jenne, L., Hauser, C., Arrighi, J. F., Saurat, J. H., and Hugin, A. W. (2000) Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Therapy 7, 1575-1583.
24. Bledsoe, A. W., Jackson, C. A., McPherson, S., and Morrow, C. D. (2000) Cytokine production in motor neurons by poliovirus replicon vector gene delivery. Nature Biotechnol. 18, 964-969.
25. Borst, E. and Messerle, M. (2000) Development of a cytomegalovirus vector for somatic gene therapy. Bone Marrow Transpl. 2, S80-S82.
26. Stevenson, A. J., Clarke, D., Meredith, D. M., Kinsey, S. E., Whitehouse, A., and Bonifer, C. (2000) Herpesvirus saimiri-based gene delivery vectors maintain heterologous expression throughout mouse embryonic stem cell differentiation in vitro. Gene Therapy 7, 464-471.
27. Tanaka, S., Iwai, M., Harada, Y., et al. (2000) Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Therapy 7, 1241-1250.
28. Fayad, R., Zhang, H., Quinn, D., Huang, Y., and Qiao,, L. (2004) Oral administration with papillomavirus pseudovirus encoding IL-2 fully restores mucosal and systemic immune responses to vaccinations in aged mice. J. Immunol. 173, 2692-2698.
29. Yamada, T., Ueda, M., Seno, M., Kondo, A., Tanizawa, K., and Kuroda, S. (2004) Novel tissue and cell type-specific gene/drug delivery system using surface engineered hepatitis B virus nano-particles. Current Drug Targets - Infect. Dis. 4, 163-167.
30. Guo, Z. S., and Bartlett, D. L. (2004) Vaccinia as a vector for gene delivery. Exp. Opin. Biol. Therapy 4, 901-917.
31. Yamanaka, R. (2004) Alphavirus vectors for cancer gene therapy. International Journal of Oncology. 24, 919-923.
32. Josephson, N. C., Trobridge, G., and Russell, D. W. (2004) Transduction of long-term and mobilized peripheral blood-derived ND/SCID repopulating cells by foamy virus vectors. Human Gene Therapy 15, 87-92.
33. Westaway, E. G., Mackenzie, J. M., and Khromykh, A. A. (2003) Kunjin RNA replication and applications of Kunjin replicons. Adv. Virus Res. 59, 99-140.
34. Nakamura, H., Kimura, T., Ikegami, H., et al. (2003) Highly efficient and minimally invasive in-vitro gene transfer to the mouse uterus using haemagglutinating virus of Japan (HJ) envelope vector. Molec. Hum. Reprod. 9, 603-609.
35. Kost, T. A., Condreay, J. P., and Jarvid, D. L. (2005) Baculovirus as versatile vector for protein expression in insect and mammalian cells. Nat. Biotechol. 23, 567-575.
36. Strayer, D. S. (1999) Gene therapy using SV40-derived vectors: what does the future hold? J. Cell. Physiol. 181, 375-384.
37. Strayer, D. S., Lamothe, M., Wei, D., Milano, J., and Kondo, R. (2001) Generation of recombinant SV40 vectors for gene transfer. In: SV40 Protocols, (Raptis, L., ed.), Humana Press, Totowa, NJ, pp. 103-117.
38. Strayer, D. S., Zern, M. A., and Chowdhury, J. R. (2002) What can SV40-derived vectors do for gene therapy? Curr. Opin. Molec. Ther. 4, 313-323.
39. Strayer, D. S., Cordelier, P., Kondo, R., et al. (2005) What they are, how they work and why they do what they do: the story of SV40-derived gene therapy vectors and what they have to offer. Curr. Gene Ther. 5, 151-165.
40. Strayer, D. S., Pomerantz, R. J., Yu, M., et al. (2000) Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors. Gene Ther. 7, 886-895.
41. Strayer, D. S. (2000) SV40-based gene transfer vectors: turning an adversary into a friend. Curr. Opin. Mol. Ther. 2, 570-578.
42. Sandalon, Z., Dalyot-Herman, N., Oppenheim, A. B., and Oppenheim, A. (1997) In vitro assembly of SV40 virions and pseudovirions: vector development for gene therapy. Hum. Gene Ther. 8, 843-849.
43. Vera, M., Prieto, J., Strayer, D. S., and Fortes, P. (2004) Factors influencing the production of recombinant SV40 vectors. Molec. Ther. 10, 780-791.
44. DeFillippis, R. A., Goodwin, E. C., Wu, L., and DiMaio, D. (2003) Endogenous human papillomavirus E6 and E7 proteins differently regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J. Virol. 77, 1551-1563.
45. Naeger, L. K., Goodwin, E. C., Hwang, E. S., DeFilippis, R. A., Zhang, H., and DiMaio, D. (1999) Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein. Cell Growth Diff. 10, 413-422.
46. Buchschacher, G. L., Jr. and Wong-Staal, F. (2000) Development of lentiviral vectors for gene therapy for human diseases. Blood 95, 2499-2504.
47. Vera, M. and Fortes, P. (2004) Simian virus-40 as a gene therapy vector. DNA Cell Biol. 23, 271-282.
48. Kimchi-Sarfati, C., Ben-Nun-Schaul, O., Rund, D., Oppenheim, A., and Gottesman, M. M. (2002) In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum. Gene Ther. 13, 299-310.
49. Fried, M. and Prives, C. (1986) The biology of simian virus 40 and polyomavirus. Cancer Cells 4, 1-16.
50. Cole, C. N. and Conzen, S. D. (2001) Polyomavirinae: the viruses and their replication, in Fields Virology, (Knipe, D. M. and Howley, P. M., eds.), Lippincott Williams and Wilkins, Philadelphia, PA, pp. 2141-2174.
51. Lane, D. P. and Crawford, L. V. (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263.
52. DeCaprio, J. A., Ludlow, J. W., Figge, J., et al. (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54, 275-283.
53. BouHamdan, M., Duan, L. -X., Pomerantz, R. J., and Strayer, D. S. (1999) Inhibition of HIV-1 by anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther. 6, 660-666.
54. Jayan, G. C., Cordelier, P., Patel, C., et al. (2001) SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters. Gene Ther. 8, 1033-1042.
55. Matskevich, A. A., Cordelier, P., and Strayer, D. S. (2003) Conditional expression of interferons α and γ activated by HBV as genetic therapy for hepatitis B. J. Interferon Cytokine Res. 23, 709-721.
56. Matskevich, A. A. and Strayer, D. S. (2005) Exploiting hepatitis C virus activation of NFκB to deliver HCV-responsive expression of interferons α and γ. Gene Ther. 10, 1861-1873.
57. Zern, M. A., Ozaki, I., Duan, L. -X., Pomerantz, R., Liu, S. -L., and Strayer, D. S. (1999) A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther. 6, 114-120.
58. Cordelier, P., Morse, B., and Strayer, D. S. (2003) Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. Oligonucleotides 13, 281-294.
59. Strayer, D. S. and Milano, J. (1996) SV40 mediates stable gene transfer in vivo. Gene Ther. 3, 581-587.
60. Strayer, D. S., Duan, L .-X., Ozaki, I., Milano, J., Bobraski, L. E., and Bagasra, O. (1997) Titering Replication-Defective virus for use in gene transfer. BioTechniques 22, 447-450.
61. Yang, Y., Ki, Q., Ertl, H. C., and Wilson, J. M. (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
62. Sauter, B. V., Parashar, B., Chowdhury, N. R., et al. (2000) Gene transfer to the liver using a replication-deficient recombinant SV40 vector results in long-term amelioration of jaundice in Gunn rats. Gastroenterol.119, 1348-1357.
63. Duan, Y. -Y., Wu, J., Zhu, J. -L., et al. (2004) Bifunctional gene therapy for human a1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterol. 127, 1222-1232.
64. Kondo, R., Feitelson, M. A., and Strayer, D. S. (1998) Use of SV40 to immunize against hepatitis B surface antigen: Implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther. 5, 575-582.
65. Pelkmans, L., Kartenbeck, J., and Helenius, A. (2001) Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat. Cell Biol. 3, 473-483.
66. Pelkmans, L., Puntener, D., and Helenius, A. (2002) Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296, 535-539.
67. McKee, H. J. and Strayer, D. S. (2002) Immune response against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector. Vaccine 20, 3613-3625.
68. Strayer, D. S., Kondo, R., Milano, J., and Duan, L.-X. (1997) Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Ther. 4, 219-225.
69. Strayer, D. S., Branco, F., Zern, M. A., et al. (2002) Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Molec. Ther. 6, 227-237.
70. Liu, B., Daviau, J., Nichols, C. N., and Strayer, D. S. (2005) In vivo gene transfer to rat bone marrow progenitor cells using rSV40 viral vectors. Blood 105, 2655-2663.
71. Goldstein, H., Pettoello-Mantovani, M., Anderson, C. M., Cordelier, P., Pomerantz, R. J., and Strayer, D. S. (2002) Gene therapy delivered in vivo using an SV40-derived vector inhibits the development of in vivo HIV-1 infection of Thy/liv-SCID/hu mice. J. Infect. Dis. 185, 1425-1430.
72. Patel, M., Cordelier, P., Strayer, D. S., and Goldstein, H. (2004) Potent in vivo inhibition of HIV-1 infection in Thy/Liv-SCID-Hu mice after in vivo treatment with a combination of SV40-derived vectors targeting CCR5 expression. Molec. Ther. 9, S141.
73. Ho, D. D. (1998) Toward HIV eradication or remission: the tasks ahead. Science 280, 1866-1867.
74. Strayer, D. S., Branco, F., Landré, J., BouHamdan, M., Shaheen, F., and Pomerantz, R. J. (2002) Combination genetic therapy to inhibit HIV-1. Molec. Ther. 5, 33-41.
75. Chen, W. Y., Bailey, E. C., McCune, S. L., Dong, J. Y., and Townes, T. M. (1997) Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. USA 94, 5798-5803.
76. McInerney, J. M., Nawrocki, J. R., and Lowrey, C. H. (2000) Long-term silencing of retroviral vectors is resistant to reversal by tricostatin A and 5-azacytidine. Gene Ther. 7, 653-663.
77. Yamano, T., Ura, K., Morishita, R., Nakajima, H., Monden, M., and Kaneda, Y. (2000) Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Molec. Ther. 1, 574-580.
78. Pannell, D. and Ellis, J. (2001) Silencing of gene expression: implications for design of retrovirus vectors. Rev. Med. Virol. 11, 205-217.
79. Rosenqvist, N., Hard, A. F., Segerstad, C., Samuelsson, C., Johansen, J., and Lundberg, C. (2002) Activation of silenced transgene expression in neural precursor cell lines by inhibitors of histone deacetylation. J. Gene Med. 4, 248-257.
80. Yao, S., Sukonnik, T., Bharadwai, R. R., Pasceri, P., and Ellis, J. (2004) Retrovirus silencing, variegation, extinction, and memory are controlled by dynamic interplay of multiple epigenetic modifications. Molec. Ther. 10, 27-36.
81. Swindle, C. S. and Klug, C. A. (2002) Mechanisms that regulate silencing of gene expression from retroviral vectors. J. Hematother. Stem Cell Res. 11, 449-456.
82. Kalberer, C. P., Pawliuk, R., Imren, S., et al. (2000) Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice. Proc. Natl. Acad. Sci. USA 97, 5411-5415.
83. Iba, H., Mizutani, T., and Ito, T. (2003) SWI/SNF chromatin remodeling complex and retroviral gene silencing. Rev. Med. Virol. 13, 99-110.
84. Swindle, C. S., Kim, H. G., and Klug, C. A. (2004) Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses silencing in embryonic stem cells. J. Biol. Chem. 279, 34-41.
85. Lung, H. Y., Meeus, I. S., Weinberg, R. S., and Atweh, G. F. (2000) In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction. Blood Cells Molec. Dis. 26, 613-619.
86. Svoboda, J., Hejnar, J., Geryk, J., Elleder, D., and Vernerova, Z. (2000) Retrovirus in foreign species and the problem of provirus silencing. Gene 261, 181-188.
87. Pannell, D., Osborne, C. S., Yao, S., et al. (2000) Retrovirus vector silencing is de nova methylase independent and marked by a repressive histone code. EMBO J. 19, 5884-5894.
88. McKee, H. J. and Strayer, D. S. (2003) Immunization against SIV Gag using recombinant SV40 vectors elicits strong, durable cell mediated immune responses. Proc. 10th Conf. Retroviruses Opportun. Infect. 10, 211.
89. McKee, H. J. and Strayer, D. S. (2003) Delivery of SIV gag together with immunostimulatory cytokines by SV40-derived vectors generates very strong antigen-specific immune responses. Molec. Ther. 7, S262.
90. McKee, H. J., T'sao, P. Y., Vera, M., Fortes, P., and Strayer, D. S. (2004) Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV gp120 ± IL-15. Genet. Vaccines Ther. 2, 1-11.
91. Calarota, S. A., Otero, M., Cordelier, P., Pomerantz, R. J., and Strayer, D. S. (2002) Transduction of primary human monocyte-derived macrophages and dendritic cells by recombinant SV40 vectors. Molec. Ther. 5, S256.
92. Wang, L., Cao, O., Swalm, B., Dobrzynski, E., Mingozzi, F., and Herzog, R. W. (2005) Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther. 12, 1453-1464.
93. Strayer, D. S., Feitelson, M. A., Sun, B., and Matskevich, A. A. (2005) Paradigms for conditional expression of RNAi molecules for use against viral targets. Meth. Enzymol. 392, 227-241.
94. Cordelier, P. and Strayer, D. S. (2003) Conditional expression of a1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV. Gene Ther. 10, 2153-2156.
95. Botchan, M., Topp, W., and Sambrook, J. (1976) The arrangement of simian virus 40 sequences in the DNA of transformed cells. Cell 9, 269-287.
96. Botchan, M., Stringer, J., Mitchison, T., and Sambrook, J. (1980) Integration and excision of SV40 DNA from the chromosome of a transformed cell. Cell 20, 143-152.
97. Mitchell, R. S., Beitzel, B. F., Shroder, A. R. W., et al. (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLOS Biol. 2, 1127-1137
98. Pajer, P., Pecenka, V., Karafiat, V., Kralova, J., Horeijsi, Z., and Svorak, M. (2003) The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma. Oncogene 22, 665-673.
99. Audit, M., Dejardin, J., Hohl, B., et al. (1999) Introduction of a cis-acting mutation in the capsid-coding gene of moloney murine leukemia virus extends its leukemogenic properties J. Virol. 73, 10,472-10,479.
100. Nusse, R., van Ooyen, A., Rijsewijk, F., van Lohuizen, M., Schuring, E., and van't Veer, L. (1985) Retroviral insertional mutagenesis in murine mammary cancer. Proc. Royal Soc. London - Ser. B: Biol. Sci. 226, 3-13.
101. Narayanan, R., Srinivasan, A., and Aaronson, S. A. (1984) Sequences in the long terminal repeats of the Moloney murine sarcoma virus: 124 genome which control transforming gene function. Virol. 137, 32-40.
102. Hanecak, R., Pattengale, P. K., and Fan, H. (1991) Deletion of a GC-rich region flanking the enhancer element within the long terminal repeat sequences alters the disease specificity of Moloney murine leukemia virus. J. Virol. 65, 5357-5363.
103. Tupper, J. C., Chen, H., Hays, E. F., Bristol, G. C., and Yoshimura, F. K. (1992) Contributions to transcriptional activity and to viral leukemogenicity made by sequences within and downstream of the MCF13 murine leukemia virus enhancer. J. Virol. 66, 7080-7088.
104. Lenz, J., Celander, D., Crowther, R. L., Patarca, R., Perkins, D. W., and Haseltine, W. A. (1984) Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308, 467-470.
105. Marshall, E. (2003) Gene therapy. Second child in French trial is found to have leukemia. Science 299, 320.
106. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419.
107. Engel, B. C., Kohn, D. B., and Podsakoff, G. M. (2003) Update on gene therapy of inherited immune deficiencies. Curr. Opin. Molec. Ther. 5, 503-507.
108. Kohn, D. B., Sadelain, M., and Glorioso, J. C. (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nature Rev. Cancer 3, 477-488.